Latest research on Amprenavir

Amprenavir is a protease inhibitor used to treat HIV infection.

Latest findings

Furthermore, Ethanol exposure significantly decreased the IC50 values of Amprenavir, Darunavir, and nelfinavir but robustly elevated the IC50 of Indinavir and Ritonavir [12, 13], suggesting a differential impact of Ethanol on the binding and bio-transformation of protease inhibitors. [source, 2016]
One handicap of pharmacoenhancement with Ritonavir is the high rate of gastrointestinal side effects, especially chronic diarrhea if combined with PIs which cause low plasma Ritonavir concentrations and probably high gut concentrations of not resorbed Ritonavir, as shown with Lopinavir, Amprenavir, and saquinavir. [source, 2015]
Reports from North America noted associations between protease inhibitor (PI) exposure (Indinavir, saquinavir, Ritonavir, Amprenavir, Lopinavir) and DSP [4–7]. [source, 2015]
PIs, including saquinavir (SQV), RTV, LPV, ATV, tipranavir (TPV), Amprenavir (APV), and DRV, are common CYP3A4 inhibitors91 and would increase MVC concentrations. [source, 2015]
Patients were treated with combinations of the following medications (n): Amprenavir (3), Indinavir (2), Delavirdine (2), Emtricitabine (2), Lamivudine (9), Abacavir + Lamivudine (2), enfuvirtide (2), saquinavir (2), Lopinavir + Ritonavir (11), fosAmprenavir (1), Nevirapine (6), Ritonavir (10), atazanavir sulfate (6), Abacavir plus Zidovudine plus Lamivudine (5), Tenofovir plus Emtricitabine (2), Didanosine (2), Tenofovir disoproxil fumarate (19), nelfinavir (4), Stavudine (3), and Abacavir sulfate (6). [source, 2015]
The following antiretroviral drugs were tested in parallel: Efavirenz and etravirine, Amprenavir, Indinavir, and Darunavir. [source, 2015]
For each antiretroviral drug, the IC50 was as follows (in descending order for each drug category): Efavirenz (4.40E–02 nM) and etravirine (1.34E–02 nM) among NNRTIs; and Indinavir (13.5 nM), Amprenavir (7.17 nM), and Darunavir (6.80E–01 nM) among PIs. [source, 2015]
The treatment-experienced patients who received a PI-containing regimen over 6 years (KRB8014 and KRB4025) showed the highest level of FC in the resistance to Amprenavir, Indinavir, and Darunavir. [source, 2015]
Phenotypic drug susceptibility according to FC was generally higher for etravirine and Darunavir compared with Efavirenz, Amprenavir, and Indinavir for each pseudovirus derived from treatment-experienced patients infected with HIV-1 (Table 1 and Figure 1). [source, 2015]
Other antiretroviral drugs, such as Amprenavir, Indinavir, Efavirenz, and etravirine, exhibited somewhat different patterns between genotype and phenotype. [source, 2015]